Addyi (flibanserin) / Sprout Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Addyi (flibanserin) / Sprout Pharma
RAD 2003, NCT04743934: Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Active, not recruiting
2
44
US
Flibanserin 100 MG, Placebo, Androgen deprivation therapy
Andrew McDonald, National Cancer Institute (NCI)
Prostate Adenocarcinoma
03/25
03/26
HSDD, NCT04002661: Hypoactive Sexual Desire Disorder in Males

Recruiting
2
60
US
Flibanserin, Addyi, Placebo
Mohit Khera, Sprout Pharmaceuticals, Inc
Low Libido
10/24
12/26

Download Options